Drug Trial Radar · NCT07947966
Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
304
Planned (sponsor's estimate)
Start
Dec 14, 2026
Primary completion
Feb 2, 2028
Study completion Feb 2, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it. The study will be split into two parts, Part A and Part B. The study is looking at: * What side effects REGN20566 might cause * How much REGN20566 is in the blood at different times * If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well
Conditions
- Overweight
- Obesity
Interventions
REGN20566Drug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 16 weeks
- Severity of TEAEsTime frame: Up to 16 weeks
- Occurrence of TEAEsTime frame: Up to 27 weeks
- Severity of TEAEsTime frame: Up to 27 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.